These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12680162)

  • 61. Cumulative expression of HIF-1-alpha, Bax, Bcl-xL and P53 in human colorectal cancer.
    Wincewicz A; Sulkowska M; Koda M; Sulkowski S
    Pathology; 2007 Jun; 39(3):334-8. PubMed ID: 17558861
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence.
    Hao XP; Ilyas M; Talbot IC
    Pathobiology; 1997; 65(3):140-5. PubMed ID: 9309780
    [TBL] [Abstract][Full Text] [Related]  

  • 63. p53, Bcl-2 and C-Myc expressions in colorectal carcinoma associated with schistosomiasis in Egypt.
    Zalata KR; Nasif WA; Ming SC; Lotfy M; Nada NA; El-Hak NG; Leech SH
    Cell Oncol; 2005; 27(4):245-53. PubMed ID: 16308474
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Study of P53 protein expression in colorectal cancer.
    Sulkowska M; Famulski W; Guzińska-Ustymowicz K; Sulkowski S
    Folia Histochem Cytobiol; 2001; 39(2):157-8. PubMed ID: 11374803
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intracellular detection of Bcl-2 and p53 proteins by flow cytometry: comparison of monoclonal antibodies and sample preparation protocols.
    Zamai L; Canonico B; Gritzapis A; Luchetti F; Felici C; Della Felice M; Margomenou L; Papamichail M; Gratama JW; Papa S
    J Biol Regul Homeost Agents; 2002; 16(4):289-302. PubMed ID: 12597645
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tumour budding intensity in relation to cathepsin D expression and some clinicopathological features of colorectal cancer.
    Famulski W; Guzińska-Ustymowicz K; Sulkowska M; Chabowski A; Zalewski B; Piotrowski Z; Stasiak-Barmuta A; Sulkowski S
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():171-2. PubMed ID: 11820592
    [TBL] [Abstract][Full Text] [Related]  

  • 67. p53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior.
    Shanmugam C; Katkoori VR; Jhala NC; Grizzle WE; Siegal GP; Manne U
    J Histochem Cytochem; 2008 Mar; 56(3):305-12. PubMed ID: 18071066
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Image analysis for the evaluation of p53 expression in human cancers.
    Faranda A; Silvestrini R; Canova S; Costa A
    Anal Cell Pathol; 1996 Jul; 11(2):107-13. PubMed ID: 8844108
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.
    Ilyas M; Hao XP; Wilkinson K; Tomlinson IP; Abbasi AM; Forbes A; Bodmer WF; Talbot IC
    Gut; 1998 Sep; 43(3):383-7. PubMed ID: 9863484
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of p53 and bcl-2 expression in initial, synchronous, and metachronous colorectal adenomas.
    Watatani M; Ieda S; Kuroda K; Inui H; Nishimura K; Yasutomi M
    Surg Today; 1999; 29(8):707-12. PubMed ID: 10483743
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer.
    Hwang TS; Han HS; Choi HK; Lee YJ; Kim YJ; Han MY; Park YM
    J Gastroenterol Hepatol; 2003 Jun; 18(6):690-700. PubMed ID: 12753152
    [TBL] [Abstract][Full Text] [Related]  

  • 72. p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer?
    Poller DN; Baxter KJ; Shepherd NA
    Br J Cancer; 1997; 75(1):87-93. PubMed ID: 9000603
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Myocyte death and growth in the failing heart.
    Anversa P; Leri A; Beltrami CA; Guerra S; Kajstura J
    Lab Invest; 1998 Jul; 78(7):767-86. PubMed ID: 9690556
    [No Abstract]   [Full Text] [Related]  

  • 74. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer.
    Rogers AC; Winter DC; Heeney A; Gibbons D; Lugli A; Puppa G; Sheahan K
    Br J Cancer; 2016 Sep; 115(7):831-40. PubMed ID: 27599041
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tumour budding in colorectal cancer: what do we know and what can we do?
    De Smedt L; Palmans S; Sagaert X
    Virchows Arch; 2016 Apr; 468(4):397-408. PubMed ID: 26613731
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bcl-2 and p53 immunophenotypes in colorectal adenocarcinoma in type 2 diabetes mellitus versus non-diabetic patients.
    Popescu-Vâlceanu HC; Stoicea MC; Enache V; Bratu RM; Mustăţea P; Drăguţ RM; Rusu E; Ionescu-Tîrgovişte C; Radulian G
    Rom J Morphol Embryol; 2022; 63(3):521-528. PubMed ID: 36588490
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tumour budding - an additional prognostic factor in colorectal cancer survival.
    Kamall GH; Ulusoy C; Nikolovski A; Kamall S
    Pol J Pathol; 2023; 74(1):36-41. PubMed ID: 37306351
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Potential clinical scenarios of tumour budding in colorectal cancer.
    Dawson H; Blank A; Zlobec I; Lugli A
    Acta Gastroenterol Belg; 2019; 82(4):515-518. PubMed ID: 31950807
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review.
    van Wyk HC; Park J; Roxburgh C; Horgan P; Foulis A; McMillan DC
    Cancer Treat Rev; 2015 Feb; 41(2):151-9. PubMed ID: 25549950
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy.
    Puppa G; Senore C; Sheahan K; Vieth M; Lugli A; Zlobec I; Pecori S; Wang LM; Langner C; Mitomi H; Nakamura T; Watanabe M; Ueno H; Chasle J; Conley SA; Herlin P; Lauwers GY; Risio M
    Histopathology; 2012 Oct; 61(4):562-75. PubMed ID: 22765314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.